RT Journal
A1 Peterson WL, Cryer B
T1 COx-1–sparing nsaids—is the enthusiasm justified?
JF JAMA
JO JAMA
YR 1999
FD November 24
VO 282
IS 20
SP 1961
OP 1963
DO 10.1001/jama.282.20.1961
UL http://dx.doi.org/10.1001/jama.282.20.1961
AB 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely
used therapeutic agents today, with nearly $2 billion spent in the United
States yearly on prescription NSAIDs alone.1
By inhibiting the enzyme cyclooxygenase (COX) and decreasing prostaglandin
synthesis, these agents provide effective analgesia and suppress inflammation.
Most NSAIDs (nonselective) inhibit not only prostaglandins at sites of inflammation
but also prostaglandins that serve important functions in other parts of the
body. This inhibition may be beneficial when, for example, these drugs are
prescribed to impair normal platelet function to prevent cardiovascular events.